ミコフェノラートモフェチルとメトトレキサートとアザチオプリンを併用して,タカヤス動脈炎の治療
Xiaochuan Sun1, Jing Li2, Xinwang Duan3
1Department of Internal Medicine, Peking Union Medical College Hospital, Beijing, China.
Annals of the rheumatic diseases
|August 23, 2025
まとめ
ミコフェノラートモフェチル (MMF) とメトトレキサート (MTX) は,アクティブなタカヤス動脈炎 (TAK) の治療において,サイクロフォスファミド (CYC) とアザチオプリン (AZA) の治療に比べて,より優れた有効性を示した. この組み合わせは,TAK患者にとってよく耐える,費用対効果の高い治療法です.
科学分野:
- リウマトロジ
- 免疫学
- 血管医学
背景:
- タカヤス動脈炎 (TAK) は,大動脈に影響する希少で慢性的な炎症性疾患です.
- 現在,活性TAKの治療戦略は,しばしば免疫抑制薬を含むが,最適の治療法はまだ研究中である.
- 異なる免疫抑制剤の組み合わせを比較することは,患者のアウトカムを改善し,この珍しい血管炎の管理に不可欠です.
研究 の 目的:
- ミコフェノラートモフェチル (MMF) とメトトレキサート (MTX) と併用したアザチオプリン (AZA) と併用したアザチオプリン (CYC) の有効性と安全性を評価する.
- 28週と52週における全体的な応答率,完全応答率 (CR),部分応答率 (PR) を決定する.
- 2つの治療群における再発および重度の有害事象の発生率を評価する.
主な方法:
- 有効なTAKを持つ111人の成人を対象としたランダム化比較試験です.
- 患者は,口服MMFとMTX,または静脈内CYCと口服AZAのいずれかにランダムに割り当てられました.
- すべての患者は高用量経口グルココルチコイドを投与し,予め定義された縮小率で投与された. 主要エンドポイントは52週間の総合応答率であった.
主要な成果:
- MMF+MTX群 (n=74) は,CYC/AZA群 (n=37) と比べて,28週 (58. 1%) と52週 (55. 4%) において,全体的な応答率が著しく高かった.
- 28週と52週の両方でMMF+MTX群の完全および部分応答率も優れていた.
- 再発率はCYC/ AZA群で比較可能で,CYC/ AZA群では重篤な有害事象 (発熱した中性病) が1件あった.
結論:
- MMFとMTXを併用した治療は,ACAに続くCYCよりも,活発なタカヤス動脈炎の治療に有効です.
- MMFとMTXは好ましい有効性プロファイルを提供し,一般的によく耐受され,費用対効果が高くなります.
- この組み合わせは,アクティブなTAKの管理のための貴重な治療法であり,臨床実務での使用を支えています.
さらに関連する動画
関連する概念動画
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
267
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
267
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
231
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
231
Drugs for Treatment of Ulcerative Colitis in IBD
236
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
236
Pulmonary Tuberculosis V
238
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
238
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
202
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
202
Myocarditis III: Medical Management
15
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
15


